Biohaven Pharmaceutical
New Haven · Founded 2013
About Biohaven Pharmaceutical
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Company Facts
- Founded: 2013
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Total funding: $2.1B
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nyse:BHVN
- Website: biohavenpharma.com
- Phone: (203) 404-0410
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biohaven-pharmaceutical-62740 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.